BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New York State Department of Health Issues Clinical Laboratory Permit to Empire Genomics


11/12/2013 11:00:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Buffalo, New York - Empire Genomics, LLC (www.empiregenomics.com), an emerging molecular diagnostics company in the field of personalized medicine, announced today that its clinical laboratory facility has met the rigorous standards and obtained approval by the New York State Department of Health, and is now fully licensed (#PFI 8680) in Cytogenetics-Cancer. Simultaneously, Empire Genomics lab received Clinical Laboratory Improvements Amendments (CLIA) certification of registration (#33D2043745) from the Centers for Medicare and Medicaid Services (CMS).

Empire Genomics new clinical capabilities allow it to work closer with its biotech clients to launch Laboratory Developed Test (LDT) companion diagnostics. With the recent announcement of two biomarkers identified in myeloma and prostate cancers, they are slated to offer these biomarkers as CLIA LDT assays in 2014. This is further validation of the high quality standards Empire continues to meet in the delivery of its testing services.

"This is yet another important asset to our business and one that we are extremely proud to have obtained. It is a testament to the highly skilled and dedicated staff that we have at the Company which permits our expansion of complete genomic testing services to our clients," says Anthony Johnson, Empire Genomics President and CEO.

Dr. Theresa Brown, Clinical Lab Director at Empire Genomics, expressed We are thrilled to have received our New York State laboratory permit so we can begin providing our high quality of testing on clinical samples.

Empire Genomics will continually seek to add new tests and technologies to its menu as it deems necessary and appropriate to deliver comprehensive personalized medicine services to its customers.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES